NCT03321045View on ClinicalTrials.gov

Positron Emission Tomography (PET) Imaging with Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 21, 2017

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Breast Cancer
Interventions
DRUG

[89Zr]-Df-Trastuzumab

\[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.

DIAGNOSTIC_TEST

PET/MRI Imaging

5-6 days post injection the patients will undergo PET/MRI imaging.

Trial Locations (1)

35249

RECRUITING

The Kirklin Clinic, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER